triple negative breast cancer Archives
‘Multi-omics’ reveals treatment option for breast cancer subtype
Nov. 18, 2021— by Bill Snyder In a multidisciplinary collaboration, researchers at Vanderbilt University Medical Center and the University of Miami Miller School of Medicine have identified a subtype of triple-negative breast cancer (TNBC) that appears to be able to escape detection by the immune system and evade immunotherapy. Their report, published Nov. 1 in the journal...
Breast cancer cells ‘steal’ nutrients from immune cells: study
Apr. 1, 2021—Triple-negative breast cancer cells engage in a “glutamine steal” — outcompeting T cells for the nutrient glutamine and impairing their ability to kill tumor cells, Vanderbilt researchers have discovered.
Potential new cancer target
Jun. 4, 2020—Vanderbilt researchers have discovered the involvement of a certain type of adenosine receptor in mediating signaling that supports tumor growth and metastasis.
Triple-negative breast cancer drug therapy shows promise
Mar. 12, 2020—Researchers from Vanderbilt-Ingram Cancer Center (VICC) discovered a role for MYCN in triple-negative breast cancer (TNBC), a particularly aggressive form of the disease, and identified a potential intervention for further clinical investigation.
Breast cancer study may help predict treatment response
Feb. 27, 2020—Researchers at VUMC are reporting another advance in the understanding and treatment of triple-negative breast cancer, which is particularly aggressive and difficult to treat.
Clinical study tests drug that may prevent cancer metastasis
Jul. 8, 2019—A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.
Targeting the “un-targetable”
Nov. 18, 2016—A novel drug that targets the protein RSK blocked aggressive breast cancers from metastasizing in an animal model.
In search of new cancer targets
Sep. 9, 2016—Vanderbilt researchers developed a new algorithm to find clinically targetable gene rearrangements in cancers.
Study explores how some breast cancers resist treatment
Apr. 21, 2016—A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies.
New target for breast cancer therapy
Jul. 31, 2014—The protein MTBP is overexpressed in an aggressive type of breast cancer, and it regulates another protein implicated in many cancer types, suggesting that it may be a good target for new therapeutics.
Breast cancer study explores therapy to slow recurrence
Mar. 21, 2013—Many patients with triple-negative breast cancer (TNBC) have recurrence of their disease after an initial response to chemotherapy because the cancer cells have become resistant to treatment. TNBC has a lower survival rate because of this pattern of resistance and there are no targeted agents to treat this form of breast cancer.
